SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen® Versus Supportive Care in Patients With Myelodysplastic Syndromes

SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen® Versus Supportive Care in Patients With Myelodysplastic Syndromes

SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, that Causes Tumor Regression in AML Xenograft Models

SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, that Causes Tumor Regression in AML Xenograft Models